Список литературы

Поставить закладку

Ronco P, Debiec H. Molecular pathogenesis of membranous nephropathy. Annu Rev Pathol Mech Dis. 2020. 15:287–313
Alsharhan L, Beck LH. Membranous Nephropathy: Core Curriculum 2021. Am J Kidne Dis. 2020; XX(XX):1-14. doi:10.1053/j.ajkd.2020.10.009
Xu Z, Chen L, Xiang H et al. Advances in Pathogenesis of Idiopathic Membranous Nephropathy. Kidney Dis. 2020 Sep 6(5): 330-345. doi: 10.1159/00050770
Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11-21. doi: 10.1056/NEJMoa0810457
Debiec H, Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med 2011; 364: 689-690 doi: 10.1056/NEJMc1011678
Камышова ЕС, Бобкова ИН, Горелова И.А. и др. Генетические детерминанты развития и течения мембранозной нефропатии. Тер архив. 2018;90(6):105-111. doi.org/10.26442/terarkh2018906105-111
Бобылева ИА, Кахсуруева ПА, Камышова ЕС, Бобкова ИН и др. Изучение ассоциации вариантов гена рецептора фосфолипазы А2 М-типа (PLA2R1) с предрасположенностью к развитию идиопатической мембранозной нефропатии. Клиническая фармакология и терапия. 2019; 28(3)29-33. doi 10.32756/0869-5490-2019-3-29-33
Tomas NM, Beck LH J, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371(24):2277-2287
Xian L, Dong D, Luo J et al. Expression of THSD7A in neoplasm tissues and its relationship with proteinuria. BMC Nephrol. 2019; 20:332 https://doi.org/10.1186/s12882-019-1489-5
Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2017;12(6):983-997. doi:10.2215/CJN.11761116
Sethi S, Debiec H, Madden B, et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int. 2020;97(1):163-174. doi:10.1016/j.kint.2019.09.014
Sethi S, Debiec H, Madden B, et al. Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients. Kidney Int. 2020;98(5):1253-1264. doi:10.1016/j.kint.2020.05.030
Hayashi N, Beck LH Jr. Moore's law for membranous nephropathy. Kidney Int. 2020;98(5):1081-1084. doi:10.1016/j.kint.2020.06.020
Sethi S, Madden BJ, Debiec H, et al. Exostosin 1/Exostosin 2-Associated Membranous Nephropathy. J Am Soc Nephrol. 2019;30(6):1123-1136. doi:10.1681/ASN.2018080852
Caza TN, Hassen SI, Kuperman M, et al. Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis. Kidney Int 2020 Oct 9; S0085- 2538(20)31180-7. DOI: 10.1016/j.kint.2020.09.016
Debiec H, Guigonis V, Mougenot B. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med. 2002; 346: 2053- 2060
Ozturk S, Sumnu A, Seyahi N, et al. Demographic and clinical characteristics of primary glomerular diseases in Turkey. Int Urol Nephrol. 2014; 46(12):2347– 2355. doi: 10.1007/s11255-014-0838-3.
United States Renal Data System. USRDS annual data report: epidemiology of kidney disease in the United States. National Institutes of Health NIoDaDaK. 2018.
Hofstra JM, Wetzels JF. Introduction of a cyclophosphamide-based strategy and the risk of ESRD in patients with idiopathic membranous nephropathy: a nationwide survey in the Netherlands. Nephrol Dial Transplant. 2008;23:3534– 810. 1093/ndt/gfn350
Li LS and Liu ZH. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13519 renal biopsies. Kidney Int. 2004; 66: 920-923. doi: 10.1111/j.1523-1755.2004.00837.x
Добронравов В. А., Майер Д. А., Бережная О. В. и др. Мембранозная нефропатия в российской популяции. Тер архив. 2017;89(6):21-29. doi.org/10.17116/terarkh201789621-29
Hu R, Quan S, Wang Y, et al. Spectrum of biopsy proven renal diseases in Central China: a 10-year retrospective study based on 34,630 cases. Sci Rep. 2020;10(1):10994. doi: 10.1038/s41598-020-67910-w.
Yamaguchi M, Ando M, Yamamoto R, et al. Patient age and the prognosis of idiopathic membranous nephropathy. PLoS One. 2014; 9(10): e110376 https://doi.org/10.1371/journal.pone.0110376
Wang Y, Wang GP, Li BM, Chen QK. Clinicopathological analysis of idiopathic membranous nephropathy in young adults. Gen Mol Res. 2015;14(2):4541–4548 DOI: 10.4238/2015
Moroni G, Ponticelli C. Secondary Membranous Nephropathy. A Narrative Review. Front Med. 2020; 7:611317. doi: 10.3389/fmed.2020.611317.
Ahmad SB, Appel GB. Antigens, antibodies, and membranous nephropathy: a decade of progress. Kidney Int. 2020 Jan; 97(1):29-31. doi: 10.1016/j.kint.2019.10.009
Stehlе T, Audard V, Ronco P, Debiec Н. Phospholipase A2 receptor and sarcoidosis-associated membranous nephropathy. Nephrol Dial Transplant. 2015; 30: 1047–1050 doi: 10.1093/ndt/gfv080
Xie Q, Li Y, Xue J, et al. Renal phospholipase A2 receptor in hepatitis B virus- associated membranous nephropathy. Am J Nephrol. 2015;41(4-5):345-353. doi:10.1159/000431331
Larsen CP, Messias NC, Silva FG, et al. Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol. 2013; 26: 709–715. doi: 10.1038/modpathol.2012.207
Fogo AB, Lusco MA, Najafian B, et al. Atlas of Renal Pathology: Membranous Nephropathy. Am J Kidney Dis. 2015; 66(3):e15- e17 doi: 10.1053/j.ajkd.2015.07.006
Barbour SJ, Greenwald A, Djurdjev O, et al. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int. 2012;81(2):190-195 doi:10.1038/ki.2011.312
Боброва ЛА, Козловская НЛ. Тромбоэмболические осложнения нефротического синдрома. Тер архив 2020; 92 (6): 105–116. DOI: 10.26442/00403660.2020.06.000667
Бокерия Л.А., Затевахин И.И., Кириенко А.И. и др. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). Флебология. 2015;9(4-2):1-52.
Konstantinides S.V. Рекомендации ESC по диагностике и лечению острой легочной эмболии, разработанные в сотрудничестве с Европейским респираторным обществом (ERS), 2019. Российский кардиологический журнал. 2020;25(8):3848. doi:10.15829/1560-4071-2020-3848
American Gastroenterological Association Medical Position Statement: guidelines on intestinal ischemia [published correction appears in Gastroenterology 2000 Jul;119(1):280-1]. Gastroenterology. 2000;118(5):951-953. doi:10.1016/s0016- 5085(00)70182-x
Diaz M, Agraz I, Soler MJ. Anti-phospholipase A2 receptor antibody and spontaneous remission in membranous nephropathy. Clin Kidney J. 2019;12(1):33-35. doi:10.1093/ckj/sfy079
Polanco N, Gutiérrez E, Covarsí A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 2010;21(4):697-704. doi:10.1681/ASN.2009080861.
Kanigicherla D, Gummadova J, McKenzie EAet al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int 2013; 83: 940–948
Hoxha E, Thiele I, Zahner G et al. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol 2014; 25: 1357–1366
Seitz-Polski B, Debiec H, Rousseau A, et al. Phospholipase A2 Receptor 1 Epitope Spreading at Baseline Predicts Reduced Likelihood of Remission of Membranous Nephropathy. J Am Soc Nephrol 2018; 29: 401-408
Rodas L, Matas Garcia A, Barros X et al. Antiphospholipase A2 receptor antibody levels to predict complete spontaneous remission in primary membranous nephropathy. Clin Kidney J 2018; doi: 10.1093/ckj/sfy005.
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group: KDIGO clinical practice guideline for glomerulonephritis. Kidney Int 2012; 2(suppl 2): 139–274.
Бобкова И.Н., Лысенко (Козловская) Л.В., Цыгин А.Н., Шилов Е.М. Мембранозная нефропатия. В кн.: Нефрология. Клинические рекомендации / под ред. Е.М. Шилова, А.В. Смирнова, Н.Л. Козловской. – М.: ГЭОТАР- Медиа, 2016. – 816 с.
Zeng CH, Chen HM, Wang RS et al. Etiology and clinical characteristics of membranous nephropathy in Chinese patients. Am J Kidney Dis. 2008; 52: 691- 698 DOI:https://doi.org/10.1053/j.ajkd.2008.06.006
Xiaofan H, Jing X, Chenni G, et al. New risk score for predicting progression of membranous nephropathy. J Transl Med. 2019;17(1):41. Published 2019 Feb 8. doi:10.1186/s12967-019-1792-8
Wu MT, Lam KK, Lee WC et al. Albuminuria, proteinuria, and urinary albumin to protein ratio in chronic kidney disease. J Clin Lab Anal 2012;26(2):82-92. doi: 10.1002/jcla.21487 38
Yamaguchi M, Ando M, Katsuno T et al. Urinary protein and renal prognosis in idiopathic membranous nephropathy: a multicenter retrospective cohort study in Japan. Ren Fail. 2018 Nov; 40(1):435-441. doi: 10.1080/0886022X.2018.148786
Du Y, Li J, He F, et al. The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis. PLoS ONE. 2014; 9:e104936. doi:10.1371/journal.pone.0104936
Bobart SA, De Vriese AS, Pawar AS, et al. Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. Kidney Int. 2019; 95: 429-438. doi: 10.1016/j.kint.2018.10.021
Wiech T, Stahl RAK, Hoxha E. Diagnostic role of renal biopsy in PLA2R- antibody-positive patients with nephrotic syndrome. Mod Pathol. 2019; 32: 1320- 1328. doi.org/10.1038/s41379-019-0267-z
Hoxha E, Harendza S, Zahner G, et al. An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant. 2011;26(8):2526– 2532. doi:10.1093/ndt/gfr247
Radice A, Pieruzzi F, Trezzi B, et al. Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases. J Nephrol. 2018;31(2):271-278. doi:10.1007/s40620-017-0451-5
Li W, Zhao Y, Fu P. Diagnostic Test Accuracy of Serum Anti-PLA2R Autoantibodies and Glomerular PLA2R Antigen for Diagnosing Idiopathic Membranous Nephropathy: An Updated Meta-Analysis. Front Med (Lausanne). 2018;5:101. Published 2018 Apr 26. doi:10.3389/fmed.2018.00101
Hofstra JM, Debiec H, Short CD, et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol. 2012;23(10):1735-43. DOI: 10.1681/ASN.2012030242
De Vriese AS, Glassock RJ, Nath KA, et a. A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol. 2017;28(2):421-430 DOI: 10.1681/ASN.2016070776
Zhang Q, Huang B, Liu X, et al. Ultrasensitive Quantitation of Anti- Phospholipase A2 Receptor Antibody as A Diagnostic and Prognostic Indicator of Idiopathic Membranous Nephropathy. Sci Rep. 2017; 7(1):12049. doi: 10.1038/s41598-017-12014-1
Ruggenenti P, Debiec H, Ruggiero B, et al. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. J Am Soc Nephrol. 2015;26(10):2545-2558. doi:10.1681/ASN.2014070640
Cagnoli L.G. Solid tumors and paraneoplastic glomerulonephritis. Ital Nefrol. 2010;27 Suppl 50: S51-57
Lefaucheur C, Stengel B, Nochy D, et al. Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association. Kidney Intern 2006; 70: 1510-1517. doi:10.1038/sj.ki.5001790
Bacchetta J, Juillard L, Cochat P, Droz JP. Paraneoplastic glomerular diseases and malignancies. Crit Rev Oncol Hematol. 2009; 70: 39-58 DOI: 10.1016/j.critrevonc.2008.08.003
Beck LH. Membranous nephropathy and malignancy. Semin Nephrol. 2010; 30(6):635-44. doi: 10.1016/j.semnephrol.2010.09.011
Leeaphorn N, Kue-A-Pai P, Thamcharoen N, et al. Prevalence of cancer in membranous nephropathy: a systematic review and meta-analysis of observational studies. Am J Nephrol. 2014; 40:29–35. doi: 10.1159/000364782
Hoxha E, Beck LH Jr, Wiech T, et al. An Indirect Immunofluorescence Method Facilitates Detection of Thrombospondin Type 1 Domain-Containing 7A-Specific Antibodies in Membranous Nephropathy. J Am Soc Nephrol. 2017;28(2):520- 531. doi:10.1681/ASN.2016010050
Клинические рекомендации «Хроническая болезнь почек (ХБП)», Ассоциация нефрологов, 2021; https://rusnephrology.org/wp- content/uploads/2020/12/CKD_final.pdf
Moghazi S, Jones E, Schroepple J et al. Correlation of renal histopathology with sonographic findings. Kidney Int. 2005;67(4): 1515-1520. doi: 10.1111/j. 1523- 1755.2005.00230.x 50
Lucisano G, Comi N, Pelagi E et al. Can renal sonography be a reliable diagnostic tool in the assessment of chronic kidney disease? J Ultrasound Med. 2015;34(2):299-306. doi: 10.7863/ultra.34.2.299 46
Yaprak M, Çakır Ö, Turan MN, et al. Role of ultrasonographic chronic kidney disease score in the assessment of chronic kidney disease. Int Urol Nephrol. 2017 Jan;49(1):123-131. doi: 10.1007/s11255-016-1443-4
Whittier WL, Korbet SM. Renal biopsy: update. .Curr Opin Nephrol Hypertens. 2004; 13(6):661-5. doi: 10.1097/00041552-200411000-00013.
Bandari J, Fuller TW, Turner Іі RM, D'Agostino LA. Renal biopsy for medical renal disease: indications and contraindications. Can J Urol. 2016; 23(1):8121-6.
Клинические рекомендации «Острое повреждение почек (ОПП)». Ассоциация нефрологов, 2021 г. https://rusnephrology.org/wp- content/uploads/2020/12/AKI_final.pdf
Yang Y, Zhang Z, Zhuo L et al. The Spectrum of Biopsy-Proven Glomerular Disease in China: A Systematic Review. Chin Med J (Engl) 2018; 131(6):731-735. doi: 10.4103/0366- 6999.226906 61
Rychlik 1, Jancova E, Tesar V et al. The Czech registry of renal biopsies. Occurrence of renal diseases in the years 1994-2000. Nephrol Dial Transplant 2004;19(12):3040-9
Haider DG, Masghati S, Goliasch G et al. Kidney biopsy results versus clinical parameters on mortality and ESRD progression in 2687 patients with glomerulonephritis. Eur J Clin Invest 2014;44(6):578-86. doi: 10.1111/eci. 12274
Hoxha E, Kneibler U, Stege G, et al. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int. 2012; 82(7):797-804. doi: 10.1038/ki.2012.209
Svobodova B, Honsova E, Ronco P, Tesar V, Debiec H. Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. Nephrol Dial Transplant. 2013;28(7):1839-1844. doi:10.1093/ndt/gfs439.
Hanset N, Aydin S, Demoulin N et al. Podocyte antigen staining to identify distinct phenotypes and outcomes in membranous nephropathy: a retrospective multicenter cohort study. Am J Kidney Dis. 2020;76(5):624-635. doi: 10.1053/j.ajkd.2020.04.013
Xie X, Liu Y, Perkovic V, et al. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta- analysis of Randomized Clinical Trials. Am J Kidney Dis. 2016;67(5):728-741. doi:10.1053/j.ajkd.2015.10.011
Catapano F, Chiodini P, De Nicola L, et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta- analysis and metaregression. Am J Kidney Dis. 2008;52(3):475-485. doi:10.1053/j.ajkd.2008.03.008
Furumatsu Y, Nagasawa Y, Tomida K, et al. Effect of renin-angiotensin- aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin- converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res. 2008;31(1):59-67. doi:10.1291/hypres.31.59
Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148(1):30-48. doi:10.7326/0003- 4819-148-1-200801010-00190
Geng DF, Sun WF, Yang L, En G, Wang JF. Antiproteinuric effect of angiotensin receptor blockers in normotensive patients with proteinuria: a meta-analysis of randomized controlled trials. J Renin Angiotensin Aldosterone Syst. 2014;15(1):44- 51. doi:10.1177/1470320312474054
Weir MR. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Clin Ther. 2007;29(9):1803-1824. doi:10.1016/j.clinthera.2007.09.019
Heerspink HJL, Stefánsson BV, Correa-Rotte R. et al. Dapagliflozin in patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-46. doi: 10.1056/NEJMoa2024816
Wheeler DС, Stefansson BV, Batiushin M et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol Dial Transplant 2020; 35(10):1700-1711. doi: 10.1093/ndt/gfaa234
Wheeler DС, Stefansson BV, Jongs N et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021; 9(1):22-31.doi: 10.1016/S2213-8587(20)30369-7
Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney inter., Suppl. 2013; 3: 259–305.
Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2014;(5):CD007784. Published 2014 May 31. doi:10.1002/14651858.CD007784.pub2
McMahon EJ, Campbell KL, Bauer JD, Mudge DW. Altered dietary salt intake for people with chronic kidney disease. Cochrane Database Syst Rev. 2015;(2):CD010070. Published 2015 Feb 18. doi:10.1002/14651858.CD010070.pub2
Garofalo C, Borrelli S, Provenzano M, et al. Dietary Salt Restriction in Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials. Nutrients. 2018;10(6):732. Published 2018 Jun 6. doi:10.3390/nu10060732
Strom BL, Yaktine AL, Oria M, Committee on the Consequences of Sodium Reduction in Populations; Food and Nutrition Board; Board on Population Health and Public Health Practice; Sodium Intake in Populations: Assessment of Evidence. Washington (DC): National Academies Press (US); August 27, 2013.
O'Donnell M, Mente A, Rangarajan S, et al. Urinary sodium and potassium excretion, mortality, and cardiovascular events [published correction appears in N Engl J Med. 2014 Sep 25;371(13):1267]. N Engl J Med. 2014;371(7):612-623. doi:10.1056/NEJMoa1311889
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter., Suppl. 2013; 3: 1–150. doi:10.1038/kisup.2012.73
Palmer SC, Maggo JK, Campbell KL, et al. Dietary interventions for adults with chronic kidney disease. Cochrane Database Syst Rev. 2017;4(4):CD011998. Published 2017 Apr 23. doi:10.1002/14651858.CD011998.pub2
Hofstra JM, Wetzels JFM. Should aspirin be used for primary prevention of thrombotic events in patients with membranous nephropathy?. Kidney Int. 2016;89(5):981-983. doi:10.1016/j.kint.2016.01.019
Lionaki S, Derebail VK, Hogan SL, et al. Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol. 2012;7(1):43-51. doi:10.2215/CJN.04250511
Kelddal S, Nykjær KM, Gregersen JW, Birn H. Prophylactic anticoagulation in nephrotic syndrome prevents thromboembolic complications. BMC Nephrol. 2019;20(1):139. Published 2019 Apr 25. doi:10.1186/s12882-019-1336-8
Kumar S, Chapagain A, Nitsch D, Yaqoob MM. Proteinuria and hypoalbuminemia are risk factors for thromboembolic events in patients with idiopathic membranous nephropathy: an observational study. BMC Nephrol. 2012;13:107. Published 2012 Sep 10. doi:10.1186/1471-2369-13-107
Zou PM, Li H, Cai JF, et al. A Cohort Study of Incidences and Risk Factors for Thromboembolic Events in Patients with Idiopathic Membranous Nephropathy. Chin Med Sci J. 2018;33(2):91-99. doi:10.24920/11809
Glassock RJ. Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. J Am Soc Nephrol. 2007;18(8):2221-2225. doi:10.1681/ASN.2006111300
Gyamlani G, Molnar MZ, Lu JL, Sumida K, Kalantar-Zadeh K, Kovesdy CP. Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome. Nephrol Dial Transplant. 2017;32(1):157-164. doi:10.1093/ndt/gfw227
van de Logt AE, Hofstra JM, Wetzels JF. Pharmacological treatment of primary membranous nephropathy in 2016. Expert Rev Clin Pharmacol 2016; 9: 1463-1478
Bellomo R, Atkins RC. Membranous nephropathy and thromboembolism: is prophylactic anticoagulation warranted?. Nephron. 1993;63(3):249-254. doi:10.1159/000187205
Barbour SJ, Greenwald A, Djurdjev O, et al. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int. 2012;81(2):190-195. doi:10.1038/ki.2011.312

Mahmoodi B.K., ten Kate M.K., Waanders F. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation. 2008;117:224–230.
Lee T, Biddle AK, Lionaki S, et al. Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy. Kidney Int. 2014;85(6):1412-1420. doi:10.1038/ki.2013.476
Lee T, Derebail VK, Kshirsagar AV, et al. Patients with primary membranous nephropathy are at high risk of cardiovascular events. Kidney Int. 2016;89(5):1111- 1118. doi:10.1016/j.kint.2015.12.041
Medjeral-Thomas N, Ziaj S, Condon M, et al. Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome. Clin J Am Soc Nephrol. 2014;9(3):478-483. doi:10.2215/CJN.07190713
Saxena R, Batra VV, Singh ND. Prothrombotic factors in nephrotic syndrome. Indian J Pathol Microbiol. 2000;43(3):319-323
Bharadwaj J, Jayaraman C, Shrivastava R. Heparin resistance. Lab Hematol. 2003;9(3):125-131.
Spiess BD. Treating heparin resistance with antithrombin or fresh frozen plasma. Ann Thorac Surg. 2008;85(6):2153-2160. doi:10.1016/j.athoracsur.2008.02.037
Zhang L, Zhang H, Zhang J, Tian H, Liang J, Liu Z. Rivaroxaban for the treatment of venous thromboembolism in patients with nephrotic syndrome and low AT-III: A pilot study. Exp Ther Med. 2018;15(1):739-744. doi:10.3892/etm.2017.5471
Radhakrishnan J. Hypercoagulability in nephrotic syndrome – UpTo-Date. https://www.uptodate.com/contents/hypercoagulability-in-nephrotic-syndrome/
Рекомендации Евразийской ассоциации терапевтов. Современные аспекты антикоагулянтной терапии в терапевтической и кардиологической практике у пациентов с нарушением функции почек. Доступно по ссылке: https://euat.ru/upload/recommendation/1566466710.pdf
Pei Y, Cattran D, Greenwood C. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 1992; 42: 960–966 doi:10.1038/ki.1992.374
Cattran DC, Pei Y, Greenwood CM et al. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int 1997; 51: 901–907.
Cattran D. Management of membranous nephropathy: when and what for treatment. J Am Soc Nephrol 2005; 16: 1188–1194 doi:https://doi.org/10.1681/ASN.2005010028
van den Brand JA, Hofstra JM, Wetzels JF. Prognostic value of risk score and urinary markers in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2012; 7: 1242-1248.
Glassock RJ. Diagnosis and Natural Course of Membranous Nephropathy. Seminars in Nephrology 2003; 23 (4): 324-332 doi:10.1016/S0270- 9295(03)00049-4
Schieppati A, Mosconi L, Perna A, et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med. 1993;329(2):85-89. doi:10.1056/NEJM199307083290203
Hladunewich MA, Troyanov S, Calafati J, Cattran DC; Metropolitan Toronto Glomerulonephritis Registry. The natural history of the non-nephrotic membranous nephropathy patient. Clin J Am Soc Nephrol. 2009;4(9):1417-1422. doi:10.2215/CJN.01330209
Kosmadakis G, Filiopoulos V, Smirloglou D, Skarlas P, Georgoulias C, Michail S. Comparison of immunosuppressive therapeutic regimens in patients with nephrotic syndrome due to idiopathic membranous nephropathy. Ren Fail. 2010;32(5):566-571. doi:10.3109/08860221003728754
Laluck Jr BJ, Cattran DC. Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy. Am J Kidney Dis 1999; 33: 1026– 1032.
Troyanov S, Wall CA, Miller JA et al. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int 2004; 66: 1199–1205
Donadio JV, Holley KE, Anderson CF, et al. Controlled trial of cyclophosphamide in idiopathic membranous nephropathy. Kidney Int 1974; 6: 431-439
Falk RJ, Hogan SL, Muller KE, et al. Treatment of progressive membranous glomerulopathy. A randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone. The Glomerular Disease Collaborative Network. Ann Intern Med 1992; 116: 438-445.
Braun N, Erley CM, Benda N, et al. Therapy of membranous glomerulonephritis with nephrotic syndrome. 5 years follow-up of a prospective, randomized multi- centre study [abstract]. Nephrol Dial Transplant 1995; 10: 967
Ponticelli C, Altieri P, Scolari F, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998; 9: 444-450
Jha V, Ganguli A, Saha TK, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 2007; 18: 1899-1904
Howman A, Chapman TL, Langdon MM et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 2013; 381: 744-751 doi: 10.1016/S0140-6736(12)61566-9
Fernández-Juárez G, Rojas-Rivera J, Logt AV, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int. 2021;99(4):986-998. doi:10.1016/j.kint.2020.10.014
van den Brand JA, van Dijk PR, Hofstra JM, et al. Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2014; 9: 1066-1073
Branten AJ, Reichert LJ, Koene RA, Wetzels JF. Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency. QJM. 1998;91(5):359-366. doi:10.1093/qjmed/91.5.359
Reichert LJ, Huysmans FT, Assmann K, et al. Preserving renal function in patients with membranous nephropathy: daily oral chlorambucil compared with intermittent monthly pulses of cyclophosphamide. Ann Intern Med 1994; 121: 328-333.
Dahan K, Debiec H, Plaisier E, et al. Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. J Am Soc Nephrol. 2017;28(1):348-358. doi:10.1681/ASN.2016040449
Fervenza FC, Appel GB, Barbour SJ, et al. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N Engl J Med. 2019;381(1):36-46. doi:10.1056/NEJMoa1814427
Qiu TT, Zhang C, Zhao HW, Zhou JW. Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: A systematic review and meta-analysis of 21 clinical trials. Autoimmun Rev. 2017;16(2):136-145. doi:10.1016/j.autrev.2016.12.005
Yuan H, Liu N, Sun GD, et al. Effect of prolonged tacrolimus treatment in idiopathic membranous nephropathy with nephrotic syndrome. Pharmacology 2013; 91: 259-266
Waldman M, Beck LH Jr, Braun M, Wilkins K, Balow JE, Austin HA 3rd. Membranous nephropathy: Pilot study of a novel regimen combining cyclosporine and Rituximab. Kidney Int Rep. 2016;1(2):73-84. doi:10.1016/j.ekir.2016.05.002
Pathak V, Venkatesan M, Regunathan-Shenk R. Low-dose Rituximab Monotherapy or in Combination with Tacrolimus Is Effective in Primary Membranous Nephropathy. KIDNEY 360. 2021;2: 336–338, doi: https://doi.org/10.34067/KID.0004672020
Dussol B, Morange S, Burtey S, et al. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. Am J Kidney Dis 2008; 52: 699-705
Chan TM, Lin AW, Tang SC, et al. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology (Carlton) 2007; 12: 576-581.
Senthil N L, Ganguli A, Rathi M, et al. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrol Dial Transplant 2008; 23: 1926-1930
Choi JY, Kim DK, Kim YW, et al. The Effect of Mycophenolate Mofetil versus Cyclosporine as Combination Therapy with Low Dose Corticosteroids in High- risk Patients with Idiopathic Membranous Nephropathy: a Multicenter Randomized Trial. J Korean Med Sci 2018; 33: e74
Peng L, Wei SY, Li LT, et al. Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy. J Formos Med Assoc 2016; 115: 11-18
Branten AJ, du Buf-Vereijken PW, Vervloet M, et al. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis 2007; 50: 248- 256
van de Logt AE, Hofstra JM, Wetzels JF. Pharmacological treatment of primary membranous nephropathy in 2016. Expert Rev Clin Pharmacol 2016; 9: 1463- 1478
Ponticelli C, Passerini P, Altieri P et al. Remissions and relapses in idiopathic membranous nephropathy. Nephrol Dial Transplant 1992; 7(Suppl 1): 85–90
Suki WN, Trimarchi H, Frommer JP. Relapsing membranous nephropathy. Response to therapy of relapses compared to that of the original disease. Am J Nephrol 1999; 19: 474–479
du Buf-Vereijken PW, Wetzels JF. Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity. Nephrol Dial Transplant 2004; 19: 2036– 2043
Segarra A, Praga M, Ramos N et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol 2009; 4: 1083–1088
Cattran DC, Greenwood C, Ritchie S, et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group. Kidney Int 1995; 47: 1130–1135.
Ruggenenti P, Fervenza FC, Remuzzi G. Treatment of membranous nephropathy: time for a paradigm shift. Nat Rev Nephrol. 2017;13(9):563–79
Chan MR, Dall AT, Fletcher KE, Lu N, Trivedi H. Outcomes in patients with chronic kidney disease referred late to nephrologists: a meta-analysis. Am J Med. 2007;120(12):1063-1070. doi:10.1016/j.amjmed.2007.04.024
Smart NA, Dieberg G, Ladhani M, Titus T. Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease. Cochrane Database Syst Rev. 2014;(6):CD007333. Published 2014 Jun 18. doi:10.1002/14651858.CD007333.pub2.
Black C, Sharma P, Scotland G, et al. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. Health Technol Assess. 2010;14(21):1-184. doi:10.3310/hta14210
National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP) [published correction appears in MMWR Recomm Rep. 2011 Jul 29;60:993]. MMWR Recomm Rep. 2011;60(2):1-64.
Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61(40):816-819.
Eddens T, Kolls JK. Pathological and protective immunity to Pneumocystis infection. Semin Immunopathol. 2015;37(2):153-162. doi:10.1007/s00281-014- 0459-z
Gingerich AD, Norris KA, Mousa JJ. Pneumocystis Pneumonia: Immunity, Vaccines, and Treatments. Pathogens. 2021;10(2):236. Published 2021 Feb 19. doi:10.3390/pathogens10020236
Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30. Published 2013 Aug 15. doi:10.1186/1710- 1492-9-30/
Floege J, Barbour SJ, Cattran DC, et al. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019;95(2):268-280. doi:10.1016/j.kint.2018.10.018